Ferring Pharmaceuticals Inc. presented study results demonstrating that ENDOMETRIN® (progesterone) Vaginal Insert provides effective luteal support compared to intramuscular (IM) progesterone-in-oil (PIO) in patients undergoing in vitro fertilization (IVF) using gonadotropin releasing hormone (GnRH) antagonist. The results were presented at the 66th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Denver, October 23 - 27, 2010.
According to the Society for Assisted Reproductive Technology (SART), approximately 140,000 IVF treatment cycles are performed each year. Since natural progesterone production may be compromised by IVF, progesterone supplementation is believed to be necessary to provide the proper support for implantation and the early stages of pregnancy. Studies have shown that luteal support with ART can result in increased pregnancy rates.
In the multicenter, randomized, open-label exploratory study, patients were randomized prior to stimulation with either MENOPUR® (menotropins for injection, USP) or rFSH and luteal support with either ENDOMETRIN>IM PIO.
"We are very encouraged by the results of this prospectively designed, open-label study which was conducted at six major IVF centers across the U.S.," said Charles E. Miller, MD, lead study investigator, The Advanced IVF Institute, Illinois. "ENDOMETRIN was well-tolerated and provides a more patient-friendly form of luteal support with comparable efficacy to PIO."
With more than three years of experience on the market, ENDOMETRIN is the number one prescribed progesterone product indicated for ART.
AI shows promise for predicting embryonic health without invasive testing